1.Summary of the best evidence for anticoagulation and bleeding risk management in patients with extracorporeal membrane oxygenation.
Xiaojing GUO ; Yubiao GAI ; Wei WANG ; Yuchen ZHANG ; Huiting SUN
Chinese Critical Care Medicine 2023;35(9):963-967
OBJECTIVE:
To evaluate and summarize the relevant evidence of anticoagulation and bleeding risk management in patients with extracorporeal membrane oxygenation (ECMO), and provide the evidence-based basis for the management of anticoagulation and bleeding during ECMO treatment.
METHODS:
According to the evidence "6S" pyramid model, all evidence on ECMO anticoagulation management and bleeding risk was searched in relevant databases, organizations and guideline websites at home and abroad. Evidence types included guidelines, expert consensus, systematic evaluation, Meta-analysis and original study. The search time limit was from May 31, 2012 to May 31, 2022. Two researchers with evidence-based research background conducted independent literature quality evaluation of the retrieved evidence, and the evidence that met the quality standards was extracted and summarized based on the opinions of industry experts.
RESULTS:
A total of 315 articles were retrieved, and 13 articles were included, including 3 guidelines, 6 expert consensus, and 4 Meta-analysis. A total of 27 best evidences were summarized from 7 aspects, including the selection of ECMO anticoagulation, anticoagulation in priming, anticoagulation in operation, anticoagulation monitoring, bleeding and treatment, thrombosis and treatment, and prevention and management of terminal limb ischemia.
CONCLUSIONS
This study provides evidence-based basis for bleeding prevention and anticoagulant management in ECMO patients. It is recommended to selectively apply the best evidence after evaluating the clinical environmental conditions of medical institutions, so as to improve the prognosis of ECMO patients.
Humans
;
Extracorporeal Membrane Oxygenation/adverse effects*
;
Blood Coagulation
;
Hemorrhage/etiology*
;
Anticoagulants/adverse effects*
;
Thrombosis/prevention & control*
;
Retrospective Studies
2.Effects of oral and intravenous tranexamic acid on perioperative blood loss after lumbar spinal canal decompression and fusion.
Mei-Tao QI ; Shu-Ying WANG ; Ling-Ting WANG ; Xue-Wu CHEN ; Wen-Hao ZHAN ; Xiao-Feng ZHU ; Hong WANG
China Journal of Orthopaedics and Traumatology 2022;35(8):736-739
OBJECTIVE:
To explore the effects of different administration methods of tranexamic acid(TXA) on the perioperative blood loss, hidden blood loss, transfusion rate and adverse reactions in lumbar spinal decompression and fusion.
METHODS:
Sixty patients who received lumbar spinal canal decompression and fusion from July 2019 to July 2020 were enrolled and divided into observation group and control group, with 30 cases in each group. The observation group was given 2 g TXA orally at 2 hours before operation, control group was given 1 g TXA for 5-10 min before skin incision and 6 hours after operation intravenously. The intraoperative blood loss, postoperative drainage, total blood loss, hidden blood loss, drainage tube removal time, blood transfusion rate, venous thrombosis rate, adverse event rate were recorded respectively. The changes of hemoglobin(Hb) and hematocrit (HCT) were observed before operation and 1, 3 days after operation.
RESULTS:
Hb and HCT at 1 and 3 days after operation were significantly improved compared with those before operation(P<0.01). However, there was no significant difference between the groups(P>0.05). There were no significant difference in amount of blood loss, postoperative drainage, total blood loss, intraoperative blood loss, hidden blood loss, postoperative drainage time, and blood transfusion rate between two groups (P>0.05). There were no venous thrombosis and adverse events occurred in both groups.
CONCLUSION
During the perioperative period of lumbar spinal decompression and fusion, oral TXA and intravenous TXA have the same effect in reducing perioperative blood loss and are safe and reliable. It is recommended that oral TXA be used to save medical costs and convenience.
Antifibrinolytic Agents/therapeutic use*
;
Blood Loss, Surgical/prevention & control*
;
Decompression
;
Humans
;
Postoperative Hemorrhage
;
Spinal Canal
;
Spinal Fusion/methods*
;
Tranexamic Acid/therapeutic use*
;
Venous Thrombosis/etiology*
3.Effect of Gastrodin on Early Brain Injury and Neurological Outcome After Subarachnoid Hemorrhage in Rats.
Xinzhi WANG ; Shuyue LI ; Jinbang MA ; Chuangang WANG ; Anzhong CHEN ; Zhenxue XIN ; Jianjun ZHANG
Neuroscience Bulletin 2019;35(3):461-470
Gastrodin is a phenolic glycoside that has been demonstrated to provide neuroprotection in preclinical models of central nervous system disease, but its effect in subarachnoid hemorrhage (SAH) remains unclear. In this study, we showed that intraperitoneal administration of gastrodin (100 mg/kg per day) significantly attenuated the SAH-induced neurological deficit, brain edema, and increased blood-brain barrier permeability in rats. Meanwhile, gastrodin treatment significantly reduced the SAH-induced elevation of glutamate concentration in the cerebrospinal fluid and the intracellular Ca overload. Moreover, gastrodin suppressed the SAH-induced microglial activation, astrocyte activation, and neuronal apoptosis. Mechanistically, gastrodin significantly reduced the oxidative stress and inflammatory response, up-regulated the expression of nuclear factor erythroid 2-related factor 2, heme oxygenase-1, phospho-Akt and B-cell lymphoma 2, and down-regulated the expression of BCL2-associated X protein and cleaved caspase-3. Our results suggested that the administration of gastrodin provides neuroprotection against early brain injury after experimental SAH.
Animals
;
Apoptosis
;
drug effects
;
Astrocytes
;
drug effects
;
metabolism
;
Benzyl Alcohols
;
administration & dosage
;
Blood-Brain Barrier
;
drug effects
;
metabolism
;
Brain
;
drug effects
;
metabolism
;
Brain Edema
;
etiology
;
prevention & control
;
Calcium
;
metabolism
;
Glucosides
;
administration & dosage
;
Glutamic Acid
;
metabolism
;
Male
;
Microglia
;
drug effects
;
metabolism
;
Neurons
;
drug effects
;
Neuroprotective Agents
;
administration & dosage
;
Oxidative Stress
;
drug effects
;
Rats, Sprague-Dawley
;
Subarachnoid Hemorrhage
;
complications
;
metabolism
;
prevention & control
4.Prevention, diagnosis and treatment of perioperative complications of bariatric and metabolic surgery.
Haifu WU ; Ming ZHONG ; Di ZHOU ; Chenye SHI ; Heng JIAO ; Wei WU ; Xinxia CHANG ; Jing CANG ; Hua BIAN
Chinese Journal of Gastrointestinal Surgery 2017;20(4):393-397
Surgical operation in treating obesity and type 2 diabetes is popularizing rapidly in China. Correct prevention and recognition of perioperation-related operative complications is the premise of ensuring surgical safety. Familiar complications of the operation include deep venous thrombosis, pulmonary artery embolism, anastomotic bleeding, anastomotic fistula and marginal ulcer. The prevention of deep venous thrombosis is better than treatment. The concrete measures contain physical prophylaxis (graduated compression stocking and intermittent pneumatic compression leg sleeves) and drug prophylaxis (unfractionated heparin and low molecular heparin), and the treatment is mainly thrombolysis or operative thrombectomy. The treatment of pulmonary artery embolism includes remittance of pulmonary arterial hypertension, anticoagulation, thrombolysis, operative thrombectomy, interventional therapy and extracorporeal membrane oxygenation (ECMO). Hemorrhage is a rarely occurred but relatively serious complication after bariatric surgery. The primary cause of anastomotic bleeding after laparoscopic gastric bypass is incomplete hemostasis or weak laparoscopic repair. The common bleeding site in laparoscopic sleeve gastrectomy is gastric stump and close to partes pylorica, and the bleeding may be induced by malformation and weak repair technique. Patients with hemodynamic instability caused by active bleeding or excessive bleeding should timely received surgical treatment. Anastomotic fistula in gastric bypass can be divided into gastrointestinal anastomotic fistula and jejunum-jejunum anastomotic fistula. The treatment of postoperative anastomotic fistula should vary with each individual, and conservative treatment or operative treatment should be adopted. Anastomotic stenosis is mainly related to the operative techniques. Stenosis after sleeve gastrectomy often occurs in gastric angle, and the treatment methods include balloon dilatation and stent implantation, and surgical treatment should be performed when necessary. Marginal ulcer after gastric bypass is a kind of peptic ulcer occurring close to small intestine mucosa in the junction point of stomach and jejunum. Ulcer will also occur in the vestige stomach after laparoscopic sleeve gastrectomy, and the occurrence site locates mostly in the gastric antrum incisal margin. Preoperative anti-HP (helicobacter pylorus) therapy and postoperative continuous administration of proton pump inhibitor (PPI) for six months is the main means to prevent and treat marginal ulcer. For patients on whom conservative treatment is invalid, endoscopic repair or surgical repair should be considered. Different surgical procedures will generate different related operative complications. Fully understanding and effectively dealing with the complications of various surgical procedures through multidisciplinary cooperation is a guarantee for successful operation.
Anastomosis, Surgical
;
adverse effects
;
Anticoagulants
;
therapeutic use
;
Bariatric Surgery
;
adverse effects
;
Catheterization
;
China
;
Conservative Treatment
;
Constriction, Pathologic
;
etiology
;
therapy
;
Digestive System Fistula
;
etiology
;
therapy
;
Endoscopy, Gastrointestinal
;
methods
;
Extracorporeal Membrane Oxygenation
;
Gastrectomy
;
adverse effects
;
Gastric Bypass
;
adverse effects
;
Gastric Mucosa
;
pathology
;
Gastric Stump
;
physiopathology
;
surgery
;
Gastrointestinal Hemorrhage
;
etiology
;
prevention & control
;
surgery
;
Hemostasis, Surgical
;
adverse effects
;
methods
;
Hemostatic Techniques
;
Heparin
;
therapeutic use
;
Humans
;
Intermittent Pneumatic Compression Devices
;
Intestine, Small
;
pathology
;
Laparoscopy
;
adverse effects
;
Margins of Excision
;
Peptic Ulcer
;
etiology
;
therapy
;
Postoperative Complications
;
diagnosis
;
prevention & control
;
therapy
;
Pulmonary Embolism
;
etiology
;
therapy
;
Stents
;
Stockings, Compression
;
Thrombectomy
;
Thrombolytic Therapy
;
Venous Thrombosis
;
etiology
;
prevention & control
;
therapy
5.Deep Vein Thrombosis in the Lower Extremities in Comatose Elderly Patients with Acute Neurological Diseases.
Shoko Merrit YAMADA ; Yusuke TOMITA ; Hideki MURAKAMI ; Makoto NAKANE
Yonsei Medical Journal 2016;57(2):388-392
PURPOSE: Comatose elderly patients with acute neurological illness have a great risk of deep vein thrombosis (DVT). In this study, the incidence of DVT and the effectiveness of early initiation of treatment were evaluated in those patients. MATERIALS AND METHODS: Total 323 patients were admitted to our ward due to neurological diseases in one year, and 43 patients, whose Glasgow Coma Scale was < or =11 and who was older than > or =60 years, were included in this study. D-dimer was measured on admission and day 7, and lower-extremity ultrasonography was performed on day 7. When DVT was positive, heparin treatment was initiated, and further evaluation of pulmonary embolism (PE) was conducted. Vena cava filter protection was inserted in PE-positive patients. Incidence of DVT and PE, alteration of D-dimer value, and effect of heparin treatment were analyzed. RESULTS: DVT was positive in 19 (44.2%) patients, and PE was in 4 (9.3%). D-dimer was significantly higher in DVT-positive group on day 7 (p<0.01). No DVT were identified in patients with ischemic disease, while 66.7% of intracerebral hemorrhage and 53.3% of brain contusion patients were DVT positive. Surgery was a definite risk factor for DVT, with an odds ratio of 5.25. DVT and PE disappeared by treatment in all cases, and no patients were succumbed to the thrombosis. CONCLUSION: Patients with hemorrhagic diseases or who undergo operation possess high risk of DVT, and initiation of heparin treatment in 7 days after admission is an effective prophylaxis for DVT in comatose elderly patients without causing bleeding.
Acute Disease
;
Aged
;
Anticoagulants/adverse effects/therapeutic use
;
Antifibrinolytic Agents/therapeutic use
;
*Coma
;
Female
;
Fibrin Fibrinogen Degradation Products/therapeutic use
;
Hemorrhage/*epidemiology
;
Heparin/adverse effects/therapeutic use
;
Humans
;
Incidence
;
Japan/epidemiology
;
Lower Extremity
;
Male
;
Middle Aged
;
Nervous System Diseases/epidemiology
;
Neurosurgical Procedures/*adverse effects
;
Pulmonary Embolism/*complications/epidemiology/prevention & control
;
Risk Factors
;
Venous Thrombosis/epidemiology/*etiology/prevention & control
6.Comparison on Oral versus Intravenous Proton Pump Inhibitors for Prevention of Bleeding after Endoscopic Submucosal Dissection of Gastric Lesions.
Yeoun Su JUNG ; Kyeong Ok KIM ; Si Hyung LEE ; Byung Ik JANG ; Tae Nyeun KIM
The Korean Journal of Gastroenterology 2016;67(2):74-80
BACKGROUND/AIMS: Although intravenous proton pump inhibitor (PPI) has been used for the prevention of post endoscopic submucosal dissection (ESD) bleeding, the route of administration has not been confirmed. The aim of the present study was to compare the efficacy of intravenous and oral PPI administration for the prevention of delayed post ESD bleeding. METHODS: Total 166 consecutive patients were randomly assigned to 30 mg lansoprazol twice a day (PO group) and 120 mg pantoprazole intravenous injection (IV group) for 48 hours. Finally, 65 patients in PO group and 87 patients in IV group were analyzed. After ESD, all patients underwent follow up endoscopy after 24 hours and were observed the symptoms of bleeding up to 60 days after ESD. RESULTS: Age, sex and use of anticoagulants were not different between groups. At follow up endoscopy after 24 hours, oozing and exposed vessel was noted in 4.6% of PO group and 8.0% of IV group and there was no significant difference. Delayed bleeding occurred in 4 of 65 patients (6.2%) in the PO group and 8 of 87 patients (9.2%) in the IV group (p>0.999). By multivariate analysis, oozing or exposed vessels at follow up endoscopy were risk factors for delayed bleeding (OR=17.5, p=0.022). CONCLUSIONS: There was no significant difference in the delayed bleeding, length of hospital stay according to the administration route. Bleeding stigmata at follow up endoscopy was risk factor of delayed bleeding. Oral PPI administration can cost-effectively replace IV PPI for prevention of post ESD bleeding.
2-Pyridinylmethylsulfinylbenzimidazoles/therapeutic use
;
*Administration, Oral
;
Aged
;
Anticoagulants/therapeutic use
;
Endoscopic Mucosal Resection/*adverse effects
;
Female
;
Gastroscopy
;
Humans
;
*Injections, Intravenous
;
Lansoprazole/therapeutic use
;
Male
;
Middle Aged
;
Odds Ratio
;
Postoperative Hemorrhage/etiology/*prevention & control
;
Prospective Studies
;
Proton Pump Inhibitors/*therapeutic use
;
Risk Factors
;
Stomach Neoplasms/surgery
7.Application of a standardised protocol for hepatic venous pressure gradient measurement improves quality of readings and facilitates reduction of variceal bleeding in cirrhotics.
Tze Tong TEY ; Apoorva GOGNA ; Farah Gillan IRANI ; Chow Wei TOO ; Hoau Gong Richard LO ; Bien Soo TAN ; Kiang Hiong TAY ; Hock Foong LUI ; Pik Eu Jason CHANG
Singapore medical journal 2016;57(3):132-137
INTRODUCTIONHepatic venous pressure gradient (HVPG) measurement is recommended for prognostic and therapeutic indications in centres with adequate resources and expertise. Our study aimed to evaluate the quality of HVPG measurements at our centre before and after introduction of a standardised protocol, and the clinical relevance of the HVPG to variceal bleeding in cirrhotics.
METHODSHVPG measurements performed at Singapore General Hospital from 2005-2013 were retrospectively reviewed. Criteria for quality HVPG readings were triplicate readings, absence of negative pressure values and variability of ≤ 2 mmHg. The rate of variceal bleeding was compared in cirrhotics who achieved a HVPG response to pharmacotherapy (reduction of the HVPG to < 12 mmHg or by ≥ 20% of baseline) and those who did not.
RESULTS126 HVPG measurements were performed in 105 patients (mean age 54.7 ± 11.4 years; 55.2% men). 80% had liver cirrhosis and 20% had non-cirrhotic portal hypertension (NCPH). The mean overall HVPG was 13.5 ± 7.2 mmHg, with a significant difference between the cirrhosis and NCPH groups (p < 0.001). The proportion of quality readings significantly improved after the protocol was introduced. HVPG response was achieved in 28 (33.3%, n = 84) cirrhotics. Nine had variceal bleeding over a median follow-up of 29 months. The rate of variceal bleeding was significantly lower in HVPG responders compared to nonresponders (p = 0.025).
CONCLUSIONThe quality of HVPG measurements in our centre improved after the introduction of a standardised protocol. A HVPG response can prognosticate the risk of variceal bleeding in cirrhotics.
Esophageal and Gastric Varices ; complications ; physiopathology ; Female ; Follow-Up Studies ; Gastrointestinal Hemorrhage ; etiology ; physiopathology ; prevention & control ; Humans ; Hypertension, Portal ; complications ; physiopathology ; Liver Cirrhosis ; complications ; physiopathology ; Male ; Middle Aged ; Portal Pressure ; physiology ; Prognosis ; Retrospective Studies
8.Role of local citrate anticoagulation in continuous blood purification to patients at high risk of bleeding in ICU.
Shangping ZHAO ; Hao OU ; Yue PENG ; Zuoliang LIU ; Mingshi YANG ; Xuefei XIAO
Journal of Central South University(Medical Sciences) 2016;41(12):1334-1339
To evaluate the safety and efficiency of citrate anticoagulant-based continuous blood purification in patients at high risk of bleeding.
Methods: One hundred and fifty-two patients at high risk of bleeding were divided into local citrate group (group A, n=68) and heparin group (group B, n=84). Clotting function, change of pH, ionized sodium, bicarbonate ion, ionized calcium, activated clotting time (ACT) and complications were monitored before and during treatment.
Results: Compared to the group A, the incidence of clotting in filter and chamber, the degree of bleeding or fresh bleeding were significantly reduced in the group B (P<0.05). ACT of post-filter at 4, 8 and 12 h during the treatment in the group A was significantly extended compared with that without treatment (P<0.05), while there was no significant change in group B (P>0.05). The pH value, the levels of ionized sodium, bicarbonate ion and ionized calcium during the treatment were maintained in normal range in both group A and group B.
Conclusion: Local citrate-based continuous blood purification can achieve effective anticoagulation and decrease the incidence of bleeding. It is an ideal choice for patients at high risk of bleeding.
Anticoagulants
;
pharmacology
;
Bicarbonates
;
blood
;
Blood Coagulation
;
drug effects
;
Blood Coagulation Tests
;
Calcium
;
blood
;
Citrates
;
Citric Acid
;
therapeutic use
;
Female
;
Hemodiafiltration
;
adverse effects
;
methods
;
Hemofiltration
;
Hemorrhage
;
etiology
;
prevention & control
;
Heparin
;
therapeutic use
;
Humans
;
Intensive Care Units
;
Male
;
Reference Values
;
Renal Dialysis
;
Sodium
;
blood
;
Treatment Outcome
9.Clinical Performance of the 1st American Academy of Orthopaedic Surgeons Clinical Guideline on Prevention of Symptomatic Pulmonary Embolism after Total Knee Arthroplasty in Korean Patients.
Young Gon NA ; Rui FANG ; Yeon Ho KIM ; Kwan Jae CHO ; Tae Kyun KIM
Journal of Korean Medical Science 2015;30(12):1865-1873
We sought to document the clinical performance of the 1st American Academy of Orthopaedic Surgeons (AAOS) guideline on the prevention of symptomatic pulmonary embolism (PE) after total knee arthroplasty (TKA) in Korean patients, in terms of the proportions of the each risk-stratified group, efficacy and safety. Consecutive 328 patients underwent TKA were preoperatively assessed for the risks of PE and bleeding and categorized into 4 groups: 1) standard risk, 2) high risk for PE, 3) high risk for bleeding, and 4) high risks both for PE and bleeding. One of three options was administered according to the groups (aspirin in group 1 or 4; enoxaparin and following aspirin in group 2; antithrombotic stocking in group 3). Incidences of symptomatic deep vein thrombosis (DVT) and PE, and major or minor bleeding complications were evaluated. Majority of the patients (86%) were assessed to be with standard risks both for PE and bleeding. No patient experienced symptomatic DVT or PE and major bleeding. Eleven percent of the patients discontinued chemoprophylaxis because of bleeding-related wound complication. In conclusion, the 1st AAOS guideline functions successfully in Korean patients undergoing TKA in terms of prevention of symptomatic DVT and PE while avoiding major bleeding complications.
Aged
;
Arthroplasty, Replacement, Knee/*adverse effects
;
Aspirin/administration & dosage
;
Cohort Studies
;
Enoxaparin/administration & dosage
;
Female
;
Fibrinolytic Agents/administration & dosage
;
Humans
;
Male
;
Middle Aged
;
Orthopedics
;
Postoperative Complications/etiology/*prevention & control
;
Postoperative Hemorrhage/etiology/prevention & control
;
*Practice Guidelines as Topic
;
Pulmonary Embolism/etiology/*prevention & control
;
Republic of Korea
;
Retrospective Studies
;
Risk Factors
;
Societies, Medical
;
Stockings, Compression
;
Venous Thrombosis/etiology/prevention & control
10.Second-Look Endoscopy after Gastric Endoscopic Submucosal Dissection for Reducing Delayed Postoperative Bleeding.
Chan Hyuk PARK ; Jun Chul PARK ; Hyuk LEE ; Sung Kwan SHIN ; Sang Kil LEE ; Yong Chan LEE
Gut and Liver 2015;9(1):43-51
BACKGROUND/AIMS: This stuy evaluated the role of a second-look endoscopy after gastric endoscopic submucosal dissection in patients without signs of bleeding. METHODS: Between March 2011 and March 2012, 407 patients with gastric neoplasms who underwent endoscopic submucosal dissection for 445 lesions were retrospectively reviewed. After the patients had undergone endoscopic submucosal dissection, they were allocated to two groups (with or without second-look endoscopy) according to the following endoscopy. The postoperative bleeding risk of the lesions was not considered when allocating the patients. RESULTS: The delayed postoperative bleeding rates did not differ between the two groups (with vs without second-look endoscopy, 3.0% vs 2.1%; p=0.546). However, a tumor in the upper-third of the stomach (odds ratio [OR], 5.353; 95% confidence interval [CI], 1.075 to 26.650) and specimen size greater than 40 mm (OR, 4.794; 95% CI, 1.307 to 17.588) were both independent risk factors for delayed postoperative bleeding. Additionally, second-look endoscopy was not related to reduced delayed postoperative bleeding. However, delayed postoperative bleeding in the patients who did not undergo a second-look endoscopy occurred significantly earlier than that in patients who underwent a second-look endoscopy (4.5 and 14.0 days, respectively, p=0.022). CONCLUSIONS: A routine second-look endoscopy after gastric endoscopic submucosal dissection is not necessary for all patients.
Female
;
Gastrectomy/*adverse effects
;
Gastric Mucosa/surgery
;
*Gastroscopy
;
Humans
;
Male
;
Middle Aged
;
Postoperative Hemorrhage/diagnosis/etiology/*prevention & control
;
Retrospective Studies
;
Risk Factors
;
Second-Look Surgery
;
Stomach/pathology/surgery
;
Stomach Neoplasms/pathology/surgery
;
Time Factors

Result Analysis
Print
Save
E-mail